GLP-1 Therapy Has Real Benefits and Real Risks: Here Is What Adults Need to Know

Few medications have reshaped modern healthcare as rapidly as GLP-1 receptor agonists. Originally developed for type 2 diabetes management, drugs like Semaglutide and Liraglutide have become among the most widely prescribed treatments in the United States, driven largely by their effectiveness for weight loss. But as their use has expanded to millions of patients across a broader range of conditions, what is known about both their benefits and their risks has grown significantly.

A comprehensive review published by Technology Networks examines what the current body of clinical evidence actually shows about GLP-1 therapy across multiple conditions, and the findings underscore something important: these are powerful medications that work differently depending on who is taking them and why.

On the benefits side, the evidence is compelling. Beyond their established effects on blood sugar and body weight, GLP-1 medications have been associated with meaningful reductions in major cardiovascular events in high-risk populations.

Studies have also linked their use to lower rates of substance use disorders, reduced suicidal behavior, and emerging evidence of potential benefit in neurodegenerative conditions. Some users report reductions in what is often described as food noise, the persistent mental preoccupation with eating, and others have noted improvements in mood and overall quality of life.

The risk profile, however, deserves equal attention. The most commonly reported side effects are gastrointestinal in nature: nausea, vomiting, diarrhea, and constipation, particularly during the early weeks of treatment or following dose increases.

 A significant portion of users discontinue therapy because of these effects, even though many find they diminish once the body adjusts or the dose is optimized. Notably, individuals using GLP-1 therapy for weight loss tend to experience higher rates of side effects than those using it for diabetes management, largely because weight management protocols involve higher doses and faster titration schedules.

More serious but less common risks include gallbladder disorders, acute pancreatitis, and, in patients undergoing surgery, an elevated risk of regurgitation under anesthesia if standard fasting protocols are not properly adjusted for GLP-1 use. There are also considerations around bone density loss with longer-term use, particularly relevant for women with existing osteopenia risk factors, and the importance of adequate protein intake given the appetite suppression these medications produce.

For adults considering GLP-1 therapy, or for those already taking it who want a more complete understanding of what the research shows, the most important conversation to have is with a physician who knows your full medical history. The decision to start, continue, or adjust GLP-1 treatment is not one-size-fits-all, and the right approach depends on your individual health profile, goals, and circumstances.

References / Sources

1. Technology Networks. GLP-1 Therapies: Evaluating Risks and Rewards Across Conditions. TechnologyNetworks.com.

2. National Institutes of Health. The Science of Safety: Adverse Effects of GLP-1 Receptor Agonists. PubMed Central, NIH.gov.

3. National Institutes of Health. GLP-1 Receptor Agonists in Diabetes and Weight Loss: The Double-Edged Sword of Innovation and Risks. PubMed Central, NIH.gov.